🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Excited to open Neoadjuvant trial of dd Gem-Cis in #MIBC with bladder sparing option for pts with select genetic alterations led by Gopa Iyer Alliance for Clinical Trials in Oncology Jonathan Rosenberg MD @morr316 Cleveland Clinic MD Cleveland Clinic Urology Omar Mian Bladder Cancer Advocacy Network clinicaltrials.gov/ct2/show/NCT03…

Sia Daneshmand, M.D. Peter Black Gary Steinberg Ashish M. Kamat, MD, MBBS Bladder Cancer Advocacy Network @gorejohn This remains a real concern as we move attempts at bladder preservation ahead. 5% not insignificant! Can DDR mutations in primary predict for complete nodal response as well? TBD. Gopa Iyer NCT03609216 trial should be supported. @sloan_kettering UrologyMSK

Please join me in welcoming @NimaAlmassi to the urology staff Cleveland Clinic Urology. Dr. Almassi is returning back to the GUKI family after completing a Urologic Oncology fellowship @sloan_kettering. Nima, we are all very excited to be welcoming you back.

#gupath

Cabozantinib plus Nivolumab shows a 48% objective response rate in a phase II study in non-clear cell RCC. Journal of Clinical Oncology Robert Motzer MD Memorial Sloan Kettering Cancer Center ascopubs.org/doi/abs/10.120…

For #TrialTuesday, .Gopa Iyer Memorial Sloan Kettering Cancer Center leads Alliance for Clinical Trials in Oncology trial A031701 to see how well gemcitabine hydrochloride and cisplatin work in treating patients with invasive #bladder #urothelial #cancer. Learn more: bit.ly/AllianceA031701 #NCI #NCTN #blcsm Bladder Cancer Advocacy Network